However, we do not expect significant differences between BRCA1 and BRCA2 mutation carriers in choice of (risk reducing) breast surgery, since both groups probably received similar information about the risk of (contralateral) breast cancer. This evidence concerns the gene BRCA1 and breast carcinoma.